These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2867862)

  • 21. Mucoadhesive chitosan hydrogels as rectal drug delivery vessels to treat ulcerative colitis.
    Xu J; Tam M; Samaei S; Lerouge S; Barralet J; Stevenson MM; Cerruti M
    Acta Biomater; 2017 Jan; 48():247-257. PubMed ID: 27769943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Side effects of azulfidine therapy].
    Miller B
    Med Welt; 1976 Jul; 27(27):1334-5. PubMed ID: 8688
    [No Abstract]   [Full Text] [Related]  

  • 23. Chloroquine for mild to moderately active ulcerative colitis: comparison with sulfasalazine.
    Goenka MK; Kochhar R; Tandia B; Mehta SK
    Am J Gastroenterol; 1996 May; 91(5):917-21. PubMed ID: 8633581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.
    Hanauer SB; Stathopoulos G
    Drug Saf; 1991; 6(3):192-219. PubMed ID: 1676590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sulfasalazine and folate deficiency.
    Spindel E
    JAMA; 1983 Aug; 250(7):900. PubMed ID: 6134849
    [No Abstract]   [Full Text] [Related]  

  • 26. Sulfasalazine therapy in inflammatory bowel disease.
    Das KM
    Gastroenterol Clin North Am; 1989 Mar; 18(1):1-20. PubMed ID: 2563989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sulfasalazine-induced nephrotic syndrome in a patient with ulcerative colitis.
    Molnár T; Farkas K; Nagy F; Iványi B; Wittmann T
    Inflamm Bowel Dis; 2010 Apr; 16(4):552-3. PubMed ID: 19637363
    [No Abstract]   [Full Text] [Related]  

  • 28. Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis.
    Rubin R
    Am J Gastroenterol; 1994 May; 89(5):789-91. PubMed ID: 7909645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases.
    Tremblay L; Pineton de Chambrun G; De Vroey B; Lavogiez C; Delaporte E; Colombel JF; Cortot A
    J Crohns Colitis; 2011 Oct; 5(5):457-60. PubMed ID: 21939920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative tolerability of therapies for ulcerative colitis.
    Ardizzone S; Bianchi Porro G
    Drug Saf; 2002; 25(8):561-82. PubMed ID: 12113642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sulfasalazine-induced fulminant hepatic failure.
    Marinos G; Riley J; Painter DM; McCaughan GW
    J Clin Gastroenterol; 1992 Mar; 14(2):132-5. PubMed ID: 1348259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome.
    Mogadam M; Dobbins WO; Korelitz BI; Ahmed SW
    Gastroenterology; 1981 Jan; 80(1):72-6. PubMed ID: 6108894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pulmonary diffusing capacity disorder in nonspecific intestinal inflammations unexplainable by acetylation phenotype or treatment with sulfasalazine].
    Bures J; Horácek J; Tilser P; Fixa B; Komárková O; Tichý M; Zaydlar K; Král B
    Cas Lek Cesk; 1986 Jul; 125(29):905-9. PubMed ID: 2873894
    [No Abstract]   [Full Text] [Related]  

  • 34. Sulfasalazine-induced lupus erythematosus.
    Clementz GL; Dolin BJ
    Am J Med; 1988 Mar; 84(3 Pt 1):535-8. PubMed ID: 2894766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sulfasalazine pulmonary toxicity in ulcerative colitis mimicking clinical features of Wegener's granulomatosis.
    Salerno SM; Ormseth EJ; Roth BJ; Meyer CA; Christensen ED; Dillard TA
    Chest; 1996 Aug; 110(2):556-9. PubMed ID: 8697866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Desquamative interstitial pneumonitis complicating inflammatory bowel disease of childhood.
    Teague WG; Sutphen JL; Fechner RE
    J Pediatr Gastroenterol Nutr; 1985 Aug; 4(4):663-7. PubMed ID: 2863342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current status of drug therapy for inflammatory bowel disease.
    Peppercorn MA
    Compr Ther; 1985 Dec; 11(12):14-9. PubMed ID: 2866866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Desensitization for sulfasalazine skin rash.
    Purdy BH; Philips DM; Summers RW
    Ann Intern Med; 1984 Apr; 100(4):512-4. PubMed ID: 6142671
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis.
    Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
    Gastroenterology; 1988 Jun; 94(6):1383-9. PubMed ID: 2896139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.